Cargando…

TRAF Family Member 4 Promotes Cardiac Hypertrophy Through the Activation of the AKT Pathway

BACKGROUND: Pathological cardiac hypertrophy is a major cause of heart failure morbidity. The complex mechanism of intermolecular interactions underlying the pathogenesis of cardiac hypertrophy has led to a lack of development and application of therapeutic methods. METHODS AND RESULTS: Our study pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jian, Wang, Chang‐Quan, Xiao, Wen‐Chang, Chen, Yun, Tu, Jun, Wan, Feng, Deng, Ke‐Qiong, Li, Huo‐Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547335/ https://www.ncbi.nlm.nih.gov/pubmed/37642020 http://dx.doi.org/10.1161/JAHA.122.028185

Ejemplares similares

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling
por: Ji, Yan-Xiao, et al.
Publicado: (2016)

CHIP regulates bone mass by targeting multiple TRAF family members in bone marrow stromal cells
por: Wang, Tingyu, et al.
Publicado: (2018)

TRAF Family Member-Associated NF-κB Activator (TANK) Induced by RANKL Negatively Regulates Osteoclasts Survival and Function
por: Wu, Mengrui, et al.
Publicado: (2012)

Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway
por: Liao, Hai-han, et al.
Publicado: (2019)

The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption
por: Gravallese, Ellen M, et al.
Publicado: (2001)

Novel Role for Pleckstrin Homology‐Like Domain Family A, Member 3 in the Regulation of Pathological Cardiac Hypertrophy
por: Liu, Jia, et al.
Publicado: (2019)

CD38 promotes angiotensin II‐induced cardiac hypertrophy
por: Guan, Xiao‐Hui, et al.
Publicado: (2017)

Hyperhomocysteinemia Promotes Cardiac Hypertrophy in Hypertension
por: Deng, Yawen, et al.
Publicado: (2022)

Comparison of Target Recognition by TRAF1 and TRAF2
por: Kim, Chang Min, et al.
Publicado: (2020)

TANK Promotes Pressure Overload Induced Cardiac Hypertrophy via Activating AKT Signaling Pathway
por: Pang, Yanan, et al.
Publicado: (2021)

Myotubularin-related protein 14 suppresses cardiac hypertrophy by inhibiting Akt
por: Zhang, Jie-Lei, et al.
Publicado: (2020)

LKB1IP promotes pathological cardiac hypertrophy by targeting PTEN/Akt signalling pathway
por: Tian, Mi, et al.
Publicado: (2021)

ADAM23 in Cardiomyocyte Inhibits Cardiac Hypertrophy by Targeting FAK‐AKT Signaling
por: Xiang, Mei, et al.
Publicado: (2018)

Tripartite motif 27 promotes cardiac hypertrophy via PTEN/Akt/mTOR signal pathways
por: Chen, Yan, et al.
Publicado: (2022)

Construction and analysis of cardiac hypertrophy-associated lncRNA-mRNA network based on competitive endogenous RNA reveal functional lncRNAs in cardiac hypertrophy
por: Song, Chao, et al.
Publicado: (2016)

Tripartite motif 10 regulates cardiac hypertrophy by targeting the PTEN/AKT pathway
por: Yang, Hui, et al.
Publicado: (2020)

Crystal structure of TRAF1 TRAF domain and its implications in the TRAF1-mediated intracellular signaling pathway
por: Kim, Chang Min, et al.
Publicado: (2016)

TRAF4 Promotes the Proliferation of Glioblastoma by Stabilizing SETDB1 to Activate the AKT Pathway
por: Gu, Hongyu, et al.
Publicado: (2022)

NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity
por: Zhang, Xin, et al.
Publicado: (2020)

Exploring Regulatory Mechanisms of Atrial Myocyte Hypertrophy of Mitral Regurgitation through Gene Expression Profiling Analysis: Role of NFAT in Cardiac Hypertrophy
por: Chang, Tzu-Hao, et al.
Publicado: (2016)

Functions of Autophagy in Pathological Cardiac Hypertrophy
por: Li, Zhenhua, et al.
Publicado: (2015)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2016)

Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy
por: Gupta, Ishita, et al.
Publicado: (2018)

TRAF6 Promoted Tumor Glycolysis in Non-Small-Cell Lung Cancer by Activating the Akt-HIFα Pathway
por: Feng, Lihua, et al.
Publicado: (2021)

Cardiac Hypertrophy Involves Both Myocyte Hypertrophy and Hyperplasia in Anemic Zebrafish
por: Sun, Xiaojing, et al.
Publicado: (2009)

Cardiac Hypertrophy
por: DaCosta,
Publicado: (1891)

Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas
por: Dogan, Helin, et al.
Publicado: (2022)

TRAF4 Enhances Osteosarcoma Cell Proliferation and Invasion by Akt Signaling Pathway
por: Yao, Weitao, et al.
Publicado: (2014)

Bcl-2 Is Involved in Cardiac Hypertrophy through PI3K-Akt Pathway
por: Meng, Xianwei, et al.
Publicado: (2021)

Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia
por: Tong, Wing-Hang, et al.
Publicado: (2022)

Structure of TRAF Family: Current Understanding of Receptor Recognition
por: Park, Hyun H.
Publicado: (2018)

Corrigendum: Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy
por: Gupta, Ishita, et al.
Publicado: (2018)

Taci Is a Traf-Interacting Receptor for Tall-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation
por: Xia, Xing-Zhong, et al.
Publicado: (2000)

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
por: Chen, Yan, et al.
Publicado: (2022)

Silencing COX-2 blocks PDK1/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy
por: Chen, Hongtao, et al.
Publicado: (2020)

Long non‐coding RNA cardiac hypertrophy‐associated regulator governs cardiac hypertrophy via regulating miR‐20b and the downstream PTEN/AKT pathway
por: Zhang, Mingyu, et al.
Publicado: (2019)

The function of miRNA in cardiac hypertrophy
por: Wang, Jian, et al.
Publicado: (2012)

Molecular biomarkers in cardiac hypertrophy
por: Zhu, Liu, et al.
Publicado: (2019)

Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2023)

Lysophosphatidic Acid Is Associated With Cardiac Dysfunction and Hypertrophy by Suppressing Autophagy via the LPA3/AKT/mTOR Pathway
por: Yang, Jinjing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1mbanhisfovlubpj48mnsaa5lu